Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines

被引:22
作者
Albert, Helene [1 ]
Battaglia, Eric [1 ]
Monteiro, Carolino [2 ]
Bagrel, Denyse [1 ]
机构
[1] Univ Lorraine, LIMBP SRSMC, EA 3940, F-57070 Metz, France
[2] Univ Lisbon, Fac Farm, P-1699 Lisbon, Portugal
来源
MOLECULAR ONCOLOGY | 2012年 / 6卷 / 05期
关键词
CDC25; phosphatases; Alternative splicing; Genotoxic stress; Breast cancer cells; DNA-DAMAGE; DIFFERENTIAL EXPRESSION; P53; VARIANTS; PROTEIN; CYCLE; OVEREXPRESSION; DEGRADATION; MECHANISMS; RESISTANCE;
D O I
10.1016/j.molonc.2012.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CDC25 (cell division cycle 25) phosphatases are essential for cell cycle control under normal conditions and in response to DNA damage. They are represented by three isoforms, CDC25A, B and C, each of them being submitted to an alternative splicing mechanism. Alternative splicing of many genes is affected in response to genotoxic stress, but the impact of such a stress on CDC25 splicing has never been investigated. In this study, we demonstrate that genotoxic agents (doxorubicin, camptothecin, etoposide and cisplatin), alter the balance between CDC25C splice variants in human breast cancer cell lines both at the mRNA and protein levels. This modulation occurs during the response to moderate, sub-lethal DNA damage. Our results also suggest that the CDC25C splice variants expression shift induced by a genotoxic stress is dependent on the ATM/ATR signaling but not on p53. This study highlights the modulation of CDC25C alternative splicing as an additional regulatory event involved in cellular response to DNA damage in breast cancer cells. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:542 / 552
页数:11
相关论文
共 50 条
[21]  
Hernández S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.3.CO
[22]  
2-I
[23]   Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma [J].
Hernández, S ;
Bessa, X ;
Beà, S ;
Hernández, L ;
Nadal, A ;
Mallofré, C ;
Muntane, J ;
Castells, A ;
Fernández, PL ;
Cardesa, A ;
Campo, E .
LABORATORY INVESTIGATION, 2001, 81 (04) :465-473
[24]   The DNA-damage response in human biology and disease [J].
Jackson, Stephen P. ;
Bartek, Jiri .
NATURE, 2009, 461 (7267) :1071-1078
[25]   CDC25A IS A NOVEL PHOSPHATASE FUNCTIONING EARLY IN THE CELL-CYCLE [J].
JINNO, S ;
SUTO, K ;
NAGATA, A ;
IGARASHI, M ;
KANAOKA, Y ;
NOJIMA, H ;
OKAYAMA, H .
EMBO JOURNAL, 1994, 13 (07) :1549-1556
[26]   Adjuvant therapy of breast cancer [J].
Kaklamani, VG ;
Gradishar, WJ .
CANCER INVESTIGATION, 2005, 23 (06) :548-560
[27]   Cdc25: mechanisms of checkpoint inhibition and recovery [J].
Karisson-Rosenthal, Christina ;
Millar, Jonathan B. A. .
TRENDS IN CELL BIOLOGY, 2006, 16 (06) :285-292
[28]   Differential mitotic degradation of the CDC25B phosphatase variants [J].
Kieffer, I. ;
Lorenzo, C. ;
Dozier, C. ;
Schmitt, E. ;
Ducommun, B. .
ONCOGENE, 2007, 26 (57) :7847-7858
[29]   A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy [J].
Komarov, PG ;
Komarova, EA ;
Kondratov, RV ;
Christov-Tselkov, K ;
Coon, JS ;
Chernov, MV ;
Gudkov, AV .
SCIENCE, 1999, 285 (5434) :1733-1737
[30]   Cdc25 phosphatases and cancer [J].
Kristjánsdóttir, K ;
Rudolph, J .
CHEMISTRY & BIOLOGY, 2004, 11 (08) :1043-1051